

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Abatacept for the treatment of juvenile idiopathic arthritis

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

<b>Version of matrix of consultees and commentators reviewed:</b>					
Provisional matrix of consultees and commentators sent for consultation					
<b>Summary of comments, action taken, and justification of action:</b>					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	<i>Comparative manufacturers should include Infliximab (Schering-Plough).</i>	<i>British Society of Paediatric and Adolescent Rheumatology (BSPAR) and Royal College of Paediatrics and Child Health</i>		<i>Added</i>	<i>Schering-Plough (Infliximab) have been added to the matrix as a comparator manufacturer</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Abatacept for the treatment of juvenile idiopathic arthritis

Issue date: February 2009

2.	<p><i>I do not believe the following professional groups are appropriate to contribute to this appraisal:</i></p> <p><i>Royal College of Surgeons British Orthopaedic Society British Pain Society Rheumatoid Arthritis Surgical Society</i></p>	<p><i>British Society of Paediatric and Adolescent Rheumatology (BSPAR) and Royal College of Paediatrics and Child Health</i></p>	Noted	<p><i>The Royal College of Surgeons, British Orthopaedic Society, British Pain Society and Rheumatoid Arthritis Surgical Society meet the inclusion criteria for this topic and therefore not been removed from the matrix</i></p>
3.	<p><i>In addition I am not sure of the role of Bone Research Society, British Society of Rehabilitation Medicine, The Royal Society of Medicine – Intellectual Disabilities Forum.</i></p>	<p><i>British Society of Paediatric and Adolescent Rheumatology (BSPAR) and Royal College of Paediatrics and Child Health</i></p>	Noted	<p><i>The Bone Research Society, British Society of Rehabilitation Medicine, Royal Society of Medicine – Intellectual Disabilities Forum meet the inclusion criteria for this topic and therefore have not been removed from the matrix</i></p>
4.	<p><i>The use of the research skills of the Rheumatology Medicines for Children Research Network should be considered.</i></p>	<p><i>British Society of Paediatric and Adolescent Rheumatology (BSPAR) and Royal College of Paediatrics and Child Health</i></p>	Added	<p><i>The Rheumatology Medicines for Children Research Network meets the inclusion criteria for this topic and have been therefore added to the matrix.</i></p>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Abatacept for the treatment of juvenile idiopathic arthritis

Issue date: February 2009

5.	<i>Chartered Society of Physiotherapy do not wish to take part in the appraisal</i>	<i>Chartered Society of Physiotherapy</i>	<i>Removed</i>	<i>The Chartered Society of Physiotherapy do not wish to take part in this appraisal and have therefore been removed from the matrix.</i>
6.	<p><i>The following organisations should be added to the matrix:</i></p> <p><i>Action on Pain</i></p> <p><i>Arthritic Association</i></p> <p><i>Leonard Cheshire Disability</i></p> <p><i>NCH – the Children’s Charity</i></p> <p><i>Royal College of Pathologists</i></p> <p><i>National Association of Primary Care</i></p> <p><i>Arthritis Research Campaign</i></p> <p><i>MRC Clinical Trials Unit</i></p> <p><i>National Institute of Health Research</i></p> <p><i>United Kingdom Clinical Research Network</i></p>	<i>NICE Secretariat</i>	<i>Added</i>	<i>All the organisations proposed meet the inclusion criteria and have therefore been added to the matrix.</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Abatacept for the treatment of juvenile idiopathic arthritis

Issue date: February 2009

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Abatacept for the treatment of juvenile idiopathic arthritis

Issue date: February 2009